Company Filing History:
1 out of 171 
1 out of 1 
1 out of 30 
Years Active: 1991-2023
Title: Gerhard Opelz: Innovator in Immunosuppressive Therapies
Introduction
Gerhard Opelz is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of immunology, particularly in the area of transplantation and autoimmune diseases. With a total of three patents to his name, Opelz has focused on developing innovative therapies that enhance patient outcomes.
Latest Patents
Opelz's latest patents include groundbreaking work in MIC therapy for specific immunosuppression in transplantation. This invention relates to pharmaceutical compositions that utilize isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs). These compositions are designed for the prevention and treatment of organ or cell graft rejection in human graft recipients. Another significant patent is for immunosuppressive blood cells and methods of producing the same. This invention outlines a method for creating immunosuppressive blood cells that can be utilized in treating autoimmune diseases, particularly multiple sclerosis, organ graft rejection, and graft-versus-host disease.
Career Highlights
Throughout his career, Gerhard Opelz has worked with prominent companies such as Fresenius AG and Tolerogenixx GmbH. His experience in these organizations has allowed him to apply his innovative ideas in practical settings, contributing to advancements in medical therapies.
Collaborations
Opelz has collaborated with esteemed colleagues, including Peter Terness and Christian Kleist. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the development of new therapeutic approaches.
Conclusion
Gerhard Opelz stands out as a pioneering inventor in the field of immunosuppressive therapies. His patents and collaborations reflect his commitment to improving patient care in transplantation and autoimmune diseases. His work continues to influence the medical community and offers hope for future advancements in treatment options.